Related by context. All words. (Click for frequent words.) 86 Phase 1b clinical 83 phase IIa clinical 83 Phase Ib II 81 phase IIa 81 Phase Ib 80 Phase 1a clinical 80 Phase IIa clinical 80 phase IIb clinical 79 Phase Ia 79 Phase 2a clinical 79 multicenter Phase II 79 Phase Ib study 79 Phase IIIb clinical 79 phase IIb 79 Phase 1b 78 Phase 1b trial 78 Phase 2b study 78 phase Ib 77 phase Ib clinical 77 Phase IIb clinical 77 Phase 2a 77 Phase #b/#a 77 Phase IIa 76 multicenter Phase 76 Phase 2b trial 76 dose escalation clinical 76 Phase 2a trial 76 Phase 2b clinical 76 Phase III clinical 76 placebo controlled clinical 76 placebo controlled Phase 76 Phase 1a 75 Phase IIa trial 75 phase IIb trial 75 Phase IIB 75 Phase III randomized controlled 75 phase 2a 75 dose escalation Phase 75 Phase 2b clinical trials 75 Phase #b/#a clinical 75 Phase IIb 74 dose escalation trial 74 Phase IIb trials 74 Phase IIa trials 74 BRIM2 74 Phase IIb III 74 phase IIb study 74 Phase III 74 BRIM3 74 elotuzumab 74 Phase 1b clinical trials 74 placebo controlled Phase III 74 APEX PD 74 Phase #/#a 74 multicenter randomized controlled 73 alvespimycin 73 randomized Phase IIb 73 ongoing Phase 1b 73 INCB# [001] 73 MEND CABG 73 pivotal bioequivalence 73 blinded randomized placebo controlled 73 Phase III psoriasis 73 Phase IIb trial 73 Phase IIIb 73 FOLOTYN ® 73 Phase 2b 72 confirmatory Phase III 72 Phase IIA 72 Phase Ib IIa 72 JAK inhibitor 72 Phase II 72 phase IIIb 72 Cloretazine ® 72 randomized controlled Phase 72 pivotal Phase III 72 Phase Ib clinical trials 72 TMC# C# 72 axitinib 72 multicenter randomized placebo controlled 72 GLP toxicology studies 72 ADVANCE PD 72 LUX Lung 71 pertuzumab 71 TASKi2 71 Phase IIb clinical trials 71 multicenter phase 71 PSMA ADC 71 evaluating tivozanib 71 randomized Phase 2b 71 Cloretazine R VNP#M 71 rALLy clinical trial 71 randomized Phase III 71 fosbretabulin 71 mertansine 71 multicenter clinical 71 Dacogen injection 71 pharmacokinetic PK study 71 Phase 2b kidney transplant 71 dose escalation study 71 Phase IIIb study 71 pharmacokinetics PK 71 Initiate Phase 71 sunitinib malate 71 preclinical efficacy 71 NO# [002] 71 CHAMPION PCI 71 AEGR 71 Cloretazine 70 treatment naive genotype 70 oral ridaforolimus 70 phase IIb III 70 midstage clinical 70 midstage trials 70 NP2 Enkephalin 70 HGS# 70 riociguat 70 multicentre randomized 70 registrational 70 Phase #b/#a trial 70 Phase III placebo controlled 70 CAMMS# 70 ZACTIMA 70 dacetuzumab 70 multicenter Phase III 70 double blinded randomized 70 ToGA 70 huC# DM4 70 tesmilifene 70 Androxal TM 70 davunetide intranasal AL 70 Phase III Pivotal 70 huN# DM1 70 VNP#M 70 AKT inhibitor 70 Hsp# Inhibitor 69 Pivotal Phase III 69 clinical trial 69 HuMax EGFr 69 MGd 69 neratinib 69 pharmacokinetic PK 69 relapsing multiple sclerosis 69 TG MV 69 receptor tyrosine kinase inhibitor 69 ATL# [001] 69 oral deforolimus 69 Azedra 69 ENDEAVOR III 69 Randomized Phase 69 PSN# [002] 69 RSD# oral 69 assessing T DM1 69 IIa trial 69 trastuzumab DM1 T DM1 69 prospective multicenter 69 relapsed refractory multiple myeloma 69 pharmacodynamic PD 69 STRIDE PD 69 Phase III randomized 69 initiated Phase Ib 69 Annamycin 69 Ozarelix 69 CEQ# 69 SCH # 69 Phase III clinical trials 69 BCIRG 69 confirmatory clinical 69 DermaVir Patch 69 TLK# 69 IIa clinical 69 Phase #/#a clinical 69 YONDELIS 69 EXPLORE Xa 69 phase III ACCLAIM 69 Amrubicin 69 glufosfamide 69 AVADO 69 velafermin 69 OvaRex ® MAb 69 Aflibercept 69 dirucotide 69 tramiprosate Alzhemed TM 69 Sym# 69 fostamatinib 69 Phase 2a clinical trials 69 trastuzumab emtansine T DM1 69 ELACYT 69 TASKi3 69 Sapacitabine 69 IMA# 69 Omacetaxine 69 multicenter randomized Phase 69 PF # [002] 69 multiple ascending dose 69 Combination REOLYSIN R 69 pomalidomide 69 Initiated Phase 69 vascular disrupting agent 69 Quinamed 69 TMC# [002] 69 Enzastaurin 69 Phase III VISTA 69 ABSORB clinical 69 tanespimycin 69 BNC# 69 Mipomersen 69 CRLX# 69 initiate Phase 1b 69 deforolimus 69 Aplidin 69 investigational protease inhibitor 69 Fx #A 69 depsipeptide 68 ganetespib 68 oral prodrug 68 CA4P 68 forodesine 68 GetGoal Phase III 68 Daclizumab 68 vidofludimus 68 Prostate AdenoCarcinoma Treatment 68 galiximab 68 PXD# 68 teriflunomide 68 KRN# 68 Xanafide 68 MAGE A3 ASCI 68 histone deacetylase HDAC inhibitor 68 R#/MEM # 68 thorough QT 68 refractory CLL 68 multicenter placebo controlled 68 HCV SPRINT 68 EOquin TM 68 CBLC# 68 Blinatumomab 68 ascending dose 68 Degarelix 68 Safinamide 68 HCV RESPOND 2 68 solithromycin 68 PEG SN# 68 double blinded placebo 68 lintuzumab 68 TAXUS ATLAS 68 Phase 2b Clinical Trial 68 randomized multicenter 68 II Clinical Trial 68 ENDEAVOR IV 68 dose cohort 68 Phase III confirmatory 68 lomitapide 68 Vicriviroc 68 APTIVUS 68 CLARITY study 68 elacytarabine 68 MEND CABG II 68 REVIVE Diabetes 68 AEG# 68 trodusquemine 68 GAMMAGARD 68 PDE4 inhibitor 68 Denufosol 68 DASISION 68 acyclovir Lauriad R 68 PD LID 68 TACI Ig 68 ENESTnd 68 cannabinor 68 dose escalation phase 68 HDAC Inhibitor 68 volociximab 68 DAPT 68 Tarceva TM 68 OncoGel 68 ocrelizumab 68 bicifadine 68 registrational trial 68 ZYBRESTAT fosbretabulin 68 EchoCRT 68 randomized Phase 68 PEG IFN 68 ATL/TV# 68 virus HCV protease inhibitor 68 AIR CF1 68 non nucleoside inhibitor 68 OMP #M# 68 Alocrest 68 PFO migraine 68 multicenter prospective 68 CALGB # [002] 68 relapsed MM 68 TBC# 68 Tanespimycin 68 ILLUMINATE 68 Initiates Phase II 68 randomized multicenter Phase III 68 budesonide foam 67 LUMINATE 67 ABSORB trial 67 lorvotuzumab mertansine 67 BAY #-# 67 Traficet EN 67 HPTN 67 HQK 67 Pharmacokinetics PK 67 NVA# 67 obatoclax 67 ORACLE MS 67 AQ4N 67 Zenvia ™ 67 multicenter randomized clinical 67 EVEREST II 67 Archexin 67 treatment naïve genotype 67 Phase III pivotal 67 TELINTRA 67 HGS ETR1 67 Alzhemed TM 67 initiate Phase IIb 67 olaparib 67 IL# PE#QQR 67 randomized multicentre 67 CR# vcMMAE 67 antibody MAb 67 Phase III Clinical Trial 67 alemtuzumab Campath 67 Tyrima 67 NSABP B 67 IMC #B 67 single ascending dose 67 omacetaxine mepesuccinate 67 viral kinetic 67 HGS ETR2 67 Zenvia Phase III 67 dosing cohorts 67 XL# SAR# 67 GW# [003] 67 Dacogen decitabine 67 Pivotal Trial 67 reslizumab 67 nucleotide analog 67 CARE HF 67 Silodosin 67 initiated Phase 1b 67 Plicera 67 OHR/AVR# 67 selective androgen receptor modulator 67 Phase III Psoriasis 67 initiate Phase IIa 67 Bicifadine 67 ritonavir boosted 67 ThermoDox ® clinical 67 Onconase 67 docetaxel Taxotere R 67 ONTARGET 67 sorafenib Nexavar 67 Cloretazine R 67 HuMax CD4 67 MEK inhibitor 67 Pimavanserin 67 Glufosfamide 67 randomized controlled multicenter 67 inhibitor RG# 67 IMC A# 67 Hedgehog Pathway Inhibitor 67 Tarvacin TM 67 brivaracetam 67 lumiliximab 67 SUCCEED trial 67 Telintra 67 Phase III trials 67 cilengitide 67 AIR CF2 67 Proxinium TM 67 Multiple Ascending Dose 67 multicenter randomized double 67 celgosivir 67 UPLYSO 67 PRTX 67 EndoTAG TM -1 67 romidepsin 67 polymerase inhibitor 67 Elagolix 67 VELCADE melphalan 67 Zybrestat 67 satraplatin Phase 67 Zemplar Capsules 67 refractory chronic lymphocytic 67 CB2 selective receptor agonist 67 abiraterone acetate 67 oral FTY# 67 GSK# [002] 67 CCR5 antagonist 67 RE LY ® 67 Phase IIa clinical trials 67 opioid induced bowel dysfunction 67 CALGB 66 Phase 2b monotherapy 66 BR.# 66 Asentar 66 RE SURGE 66 mapatumumab 66 entinostat 66 XL# XL# XL# 66 Ocrelizumab 66 Carfilzomib 66 pharmacodynamic profile 66 RH1 66 afatinib 66 MIST II 66 metastatic hormone refractory 66 Deforolimus 66 Pivotal Phase 66 prospective randomized multicenter 66 GRNVAC1 66 TELCYTA 66 Factor VIIa 66 Phase III registrational 66 GOUT 66 PRE SURGE 66 adecatumumab 66 lintuzumab SGN 66 enzastaurin 66 registrational Phase 66 Exherin TM 66 brivanib 66 Phase IIb kidney transplant 66 Spiegelmer ® 66 NCCTG 66 EDEMA3 66 Xelox 66 GLPG# 66 zanolimumab 66 eltrombopag 66 FOLFOX6 chemotherapy regimen 66 baminercept 66 ENMD # 66 Phase III metastatic melanoma 66 ORAL Sync 66 KNS # 66 bevirimat Study 66 CLL8 66 teduglutide 66 dirucotide MBP# 66 Phase Ib Clinical Trial 66 nab paclitaxel 66 MERLIN TIMI 66 novel VDA molecule 66 PRT# 66 oral methylnaltrexone 66 SAR# [004] 66 NOX E# 66 DEB# 66 Cethromycin 66 Bezielle 66 Medidur TM FA 66 investigational humanized monoclonal antibody 66 PEARL SC 66 Phase 2b Trial 66 CA9 SCAN 66 SPIRIT FIRST 66 OncoVEX GM CSF 66 LymphoStat B TM 66 telaprevir VX 66 fidaxomicin Phase 3 66 farletuzumab 66 visilizumab 66 MLN# 66 RhuDex ® 66 PANVAC VF 66 HuLuc# 66 OncoVex 66 ataluren 66 Triapine 66 Laquinimod 66 preclinical 66 adecatumumab MT# 66 AIM HIGH 66 RGB # 66 preclinically 66 Phase III multicenter 66 crizotinib PF # 66 cathepsin K inhibitor 66 TRO# 66 rNAPc2 66 ONCONASE R 66 Tesetaxel 66 ENDEAVOR II 66 recurrent glioblastoma multiforme 66 Pivotal Phase II 66 ORMD 66 Ceflatonin R 66 ExTRACT TIMI 66 ocular formulation 66 clinical pharmacology studies 66 EMPHASIS HF trial 66 ara C 66 bortezomib Velcade 66 Fibrillex TM 66 DSMB recommended 66 cediranib 66 CYT# potent vascular disrupting 66 recurrent malignant glioma 66 randomized multicenter trial 66 ADAGIO study 66 tolerability pharmacokinetics 66 rALLy trial 66 GALNS 66 Elocalcitol 66 IMGN# 66 dextromethorphan quinidine 66 docetaxel chemotherapy 66 pharmacodynamic effects 66 bendamustine 66 non nucleoside HCV 66 Urocidin 66 relapsing remitting multiple sclerosis 66 seliciclib CYC# 66 ASTEROID 66 PDX pralatrexate 66 gemcitabine Gemzar ® 66 VIR# 66 TG# [001] 66 PRIMO CABG 66 SYMMETRY trial 66 Dalbavancin 66 Omnitarg 66 aclidinium bromide 66 Sorafenib HCC Assessment 66 prokinetic agent 66 AZILECT R 66 hypoxia activated prodrug 66 Telcyta 66 varespladib 66 PERSEUS 66 Completes Patient Enrollment 66 COU AA 66 Romidepsin 66 VICTOR E1 66 Phase III Clinical Trials 66 Phase IIb Clinical Trial 66 diabetic neuropathic pain 66 MOZOBIL 66 Aurora kinase inhibitor 66 Phase III HEAT 66 IMPACT IMmunotherapy 66 Dyloject TM 66 pivotal Phase 66 miconazole Lauriad ® 66 vicriviroc 66 Corlux 66 dose cohorts 66 IIb clinical trial 66 Personalized Immunotherapy 66 subcutaneous formulation 66 CRMD# 66 ECASS 66 Darusentan 66 PS# DARA 66 ofatumumab HuMax CD# 65 PEGylated interferon beta 1a 65 SNT MC# 65 CUSTOM III 65 NSABP 65 oral rivaroxaban 65 PROSTVAC ® 65 oral treprostinil 65 ONTARGET R 65 pharmacokinetic studies 65 cangrelor 65 adalimumab Humira 65 tremelimumab 65 Cannabinor 65 Epratuzumab 65 severe hypercholesterolemia 65 APPRAISE 65 lexidronam injection 65 randomized blinded 65 viral kinetics 65 Teriflunomide 65 relapsed multiple myeloma 65 Saforis 65 desvenlafaxine succinate 65 CCX# 65 Myelodysplastic Syndrome MDS 65 Phase Ib IIa clinical 65 investigational pan BCR 65 evaluating carfilzomib 65 dose escalation 65 AVONEX ® 65 BRAF inhibitor 65 CIMZIA TM 65 Velcade bortezomib 65 evaluating Actimmune 65 Acute Decompensated Heart Failure 65 Bayer HealthCare Onyx Pharmaceuticals 65 OLYMPIA registry 65 Catena ® 65 Phase IIb Trial 65 stated Michelle Berrey 65 generation purine nucleoside 65 masked placebo controlled 65 Plecanatide 65 Sibutramine Cardiovascular Outcomes 65 Dextofisopam 65 Meets Primary Endpoint 65 dosing cohort 65 CTAP# Capsules 65 IIa trials 65 PhG alpha 1 65 CG# [003] 65 talabostat 65 Pivotal Study 65 PEP# [003] 65 RhuDex 65 tolevamer 65 tolerability 65 Tesmilifene 65 Phase III ALLEGRO 65 prucalopride 65 rindopepimut 65 nitazoxanide 65 preclinical studies 65 eprotirome 65 Diabetic Macular Edema 65 Phase 2a Clinical Trial 65 Phase lll 65 metastatic malignant 65 IPL# 65 Microplasmin 65 Pertuzumab 65 randomized controlled clinical 65 pharmacokinetic 65 TEMSO 65 NABTT 65 Reolysin 65 Aryplase 65 omega interferon 65 Glypromate 65 First Patient Dosed 65 CIMZIA TM certolizumab pegol 65 PROTECT AF 65 unique alkylating agent 65 Panzem R NCD 65 EOquin 65 INSPIRE Trial Phase III 65 HspE7 65 ZD# [001] 65 relapsing remitting MS RRMS 65 safety tolerability pharmacokinetic 65 Curaxin CBLC# 65 CYT# 65 Intervention Effectiveness 65 ISTODAX ® 65 trastuzumab DM1 65 Phase 2b randomized 65 Diabetic Macular Edema DME 65 ORENCIA ® 65 leukemia AML 65 ASA# 65 Ophena TM 65 ROCKET AF 65 ON #.Na 65 AeroLEF TM 65 LAF# 65 gamma secretase inhibitor 65 controlled multicenter Phase 65 placebo controlled randomized 65 Troxatyl 65 ganaxolone 65 #th Annual Interscience 65 LEP ETU 65 Successfully Completes Phase 65 initiate Phase 2b 65 BLP# Liposome Vaccine 65 maturation inhibitor 65 OXi# 65 subanalysis 65 PrevOnco 65 Initiates Phase 2b 65 Randomized Phase II 65 histamine dihydrochloride 65 preclinical pharmacokinetic 65 RG# ITMN 65 SinuNase ™ 65 orally bioavailable 65 ELND# 65 interferon gamma 1b 65 samalizumab 65 Phase III ThermoDox 65 novel histone deacetylase 65 Pemetrexed 65 GSK# [001] 65 subcutaneously administered 65 SUTENT ® 65 DXL# 65 IMPACT DCM clinical 65 Prodarsan ® 65 VA# [002] 65 GV# [001] 65 MDV# 65 cell lymphoma CTCL 65 European Sepsis Trial 65 Phase #/#a trial 65 Vitaxin 65 Aplidin R 65 LibiGel Phase III 65 PARTNER Trial 65 CCX# B 65 ThermoDox R 65 OvaRex R 65 Pafuramidine 65 clinical trials 65 lead Aganocide compound 65 ACTIVE W 65 Vion Pharmaceuticals 65 PHX# 65 Phase III Trial 65 liposomal formulation 65 placebo controlled 65 BIBW 65 Allovectin 7 65 BCX# 65 RELOVAIR ™ 65 INCB# [003] 65 intranasal formulation 65 multicenter randomized 65 metaglidasen 65 ZYBRESTAT 65 CLORETAZINE TM VNP#M 65 AVERROES 65 Afatinib 65 PEG Interferon lambda 65 Novolimus 65 Urocortin 2 65 Nuvion 65 Imprime PGG 65 NCIC CTG 65 TRX1 65 Cimzia ® certolizumab pegol 65 Initiates Enrollment 65 ALSYMPCA 65 mg/m2 cohort 65 PRECiSE 65 REOLYSIN ® 65 REG2 65 AVN# Phase 65 dexpramipexole 65 IIa clinical trial 64 PRIMO CABG2 64 Randomized Evaluation 64 Squalamine 64 GRAVITAS trial 64 CoFactor 64 Oral Fingolimod 64 Cethrin R 64 Dasatinib 64 CLL SLL 64 pharmacodynamics 64 Solorel 64 ZYBRESTAT TM 64 Interferon beta 1a 64 Elotuzumab 64 Phase IIB clinical 64 Triolex 64 randomized placebo controlled 64 HCV NS5B polymerase 64 Ixempra 64 erlotinib Tarceva ® 64 RG# [001] 64 Phase III TRIST 64 Initiates Clinical 64 Perifosine 64 Trofex 64 Myocet 64 StemEx 64 methylnaltrexone 64 telaprevir dosing 64 investigational compound 64 ANCHOR trial 64 Prosaptide 64 WX UK1 64 PI3K/Akt pathway inhibitor 64 Lu AA# 64 XmAb# 64 NXL# 64 Amoxicillin PULSYS Phase III 64 PHASE III 64 tipifarnib 64 diarrhea predominant irritable 64 Revlimid lenalidomide 64 PROMACTA 64 Aurexis 64 Dose escalation 64 doxorubicin docetaxel 64 multicentre randomized double 64 Study Evaluating 64 BioNumerik 64 Achieves Primary Endpoint 64 lenalidomide Revlimid 64 ACTEMRA TM 64 KB# [002] 64 dyskinesia PD LID 64 Protease Inhibitor 64 tiapamil 64 investigational monoclonal antibody 64 prospective multicentre 64 thalidomide Thalomid 64 Enobia 64 FOLFIRI chemotherapy 64 Proellex TM 64 Aclidinium 64 ixabepilone 64 apricitabine 64 lapatinib Tykerb 64 triphendiol 64 Clinical Trial Results 64 PF # [001] 64 Guanilib 64 Vectibix panitumumab 64 PS# [001] 64 IIa clinical trials 64 OPT CHF 64 ISIS # 64 EGFR HER2 64 IMPACT DCM 64 QLT# 64 CLARITY TIMI 64 Natalizumab 64 Golimumab 64 HuMax CD# 64 bardoxolone 64 APEX AMI trial 64 Feasibility Trial 64 canagliflozin 64 Ceflatonin 64 ALN HPN 64 tarenflurbil 64 atrasentan 64 vismodegib 64 Immunotherapeutic 64 Nexavar sorafenib 64 ascending doses 64 PA# [002] 64 PRX # 64 R#/MEM 64 anticancer compound 64 decitabine 64 TRANSFORMS 64 radiation sensitizer 64 trial evaluating PRX# 64 evaluating satraplatin 64 sitaxsentan 64 clinicaltrials 64 ACOMPLIA R 64 Phenoptin 64 demonstrated antitumor activity 64 pradefovir 64 PKC# 64 R roscovitine 64 LCP AtorFen 64 paclitaxel poliglumex 64 nucleotide analogue 64 #I TM# 64 recurrent NSCLC 64 Aeroquin 64 Initiates Phase III 64 Prospective Randomized 64 HCV protease inhibitor 64 BrachySil ™ 64 Phase 2b Study 64 MAP# 64 blinded placebo controlled 64 COSIRA trial 64 Phase IIa Clinical Trial 64 rALLy 64 Tezampanel 64 melphalan prednisone 64 rilonacept 64 DB# [003] 64 bosutinib 64 candidate CRLX# 64 safety tolerability pharmacokinetics 64 Vilazodone 64 ruxolitinib 64 PREOS 64 refractory AML 64 eosinophilic asthma 64 ADMIRE HF 64 ritonavir boosted danoprevir 64 HCD# [002] 64 LAB CGRP 64 azilsartan medoxomil 64 HER2 positive metastatic breast 64 Acute Ischemic Stroke 64 gastrointestinal disorders ATI 64 Triapine R 64 Pazopanib 64 Pharmacokinetic PK 64 Tykerb lapatinib 64 Edge STudy 64 Pralatrexate 64 orally dosed 64 Investigational Oral 64 personalized immunotherapy 64 Symadex 64 REMINYL ® 64 randomized discontinuation trial 64 metastatic castration resistant 64 AACR NCI EORTC 64 goserelin 64 prospective randomized controlled 64 Folfox 64 Ridaforolimus 64 confirmatory Phase 3 64 Thorough QT 64 initiate Phase Ib 64 velafermin belinostat 64 cariprazine 64 eritoran 64 iclaprim 64 ancrod 64 icatibant 64 prospective multicenter randomized 64 pralatrexate injection 64 Dose Ranging Study 64 safinamide 64 incyclinide 64 Ostarine 64 investigational hepatitis C 64 Presents Preclinical Data 64 arzoxifene 64 proteasome inhibitor 64 sargramostim 64 interferon beta 1b 64 BCR ABL inhibitor 64 MIRCERA 64 HIV integrase inhibitor 64 CAMPATH 64 Lisofylline LSF 64 TG# [003] 64 Ophena 64 carfilzomib 64 prospective observational 64 pain palliation 64 evaluating mipomersen 64 isavuconazole 64 ANTEGREN 64 AIR2 Trial 64 PNP inhibitor 64 Randomised 64 Endovascular Valve Edge 64 RE LY 64 OncoVEX 64 Phase 1b dose escalation 64 TMC# r 64 null responder HCV 64 double blind placebo 64 maximally tolerated dose 64 CD# monoclonal antibody 64 ALN VSP Phase 64 Maximum Tolerated Dose MTD 64 Dapagliflozin 64 recurrent glioblastoma 64 EVIZON TM 64 dexanabinol 64 label multicenter 64 Tocosol Paclitaxel 64 lenalidomide Revlimid R 64 Harry Palmin President 64 Multicenter 64 Kahalalide F 64 ProSavin 64 beta 1a 64 ATAC Arimidex Tamoxifen Alone 64 Oral NKTR 64 figitumumab 64 Randomized Double blind 64 imetelstat 64 Allovectin 7 R 64 vemurafenib 64 ACAPODENE 64 atacicept 64 CTCE 64 Orazol 64 EURIDIS 64 ALN TTR# 64 BrachySil TM 64 MADIT II 64 Alinia 64 Temsirolimus 64 Phase IIb dose 64 Early Relapsing Multiple 64 Novel Oral 64 SABCS 64 CIMZIA ™ 64 iSONEP